GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Lixte Biotechnology
Lixte Biotechnology is an oncology company developing drugs that enhance the effectiveness of chemotherapy. Its stock price is highly speculative and depends on the results of clinical trials.
Share prices of companies in the market segment - General oncology therapy
Lixte Biotechnology is an oncology company developing drugs that improve the effectiveness of standard chemotherapy and radiation therapy. We've categorized it as a "General Oncology" company. The chart below shows how the market values companies that improve existing cancer treatments.
Broad Market Index - GURU.Markets
Lixte Biotechnology is an oncology company developing drugs that inhibit phosphatases, making cancer cells more vulnerable to standard therapy. Its innovative approach makes it a component of the GURU.Markets index. The chart below compares its performance to the market.
Change in the price of a company, segment, and market as a whole per day
LIXT - Daily change in the company's share price Lixte Biotechnology
Lixte Biotechnology Holdings' daily price change reflects the high volatility inherent in biotech companies. This indicator measures sensitivity to news about the clinical trials of its oncology drugs, serving as a risk assessment element.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Lixte Biotechnology Holdings, Inc. is an oncology company. This chart demonstrates the extreme volatility of the biotech sector. Comparison with LIXT's performance, which depends on clinical trial results, helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Lixte Biotechnology is a biotech company developing drugs to treat oncology. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Lixte Biotechnology
For Lixte Biotechnology Holdings, the year-to-date performance is a story about the development of its phosphatase inhibitors. Its 12-month market cap depends entirely on early clinical trial data, where it must prove that its drugs can improve the effectiveness of standard chemotherapy and radiation therapy in cancer treatment.
Annual dynamics of market capitalization of the market segment - General oncology therapy
As an early-stage biotech, Lixte is a high-risk bet on science. Its performance is completely disconnected from the sector and depends on news about the clinical trials of its cancer drugs. Its stock price will reflect investors' speculative belief in the potential of its unique developments.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lixte Biotechnology is a clinical-stage biotech company whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Lixte Biotechnology
Lixte Biotechnology is a clinical-stage oncology company. Its monthly performance directly reflects news from its clinical trials. Any data on its phosphatase inhibitors triggers an immediate and strong investor reaction, typical of biotech.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Lixte Biotechnology is an oncology company developing drugs that make cancer cells more vulnerable to traditional chemotherapy and radiation therapy. This strategy enhances the effectiveness of existing treatments. The dynamics of the biotech sector reflect the overall context in which Lixte is trying to prove that its approach can significantly improve patient outcomes.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Lixte Biotechnology Holdings, Inc. is a clinical-stage biopharmaceutical company developing a new class of oncology drugs that enhance the effectiveness of chemotherapy. The company's future depends on the success of its clinical trials. The broader market chart serves only as a backdrop to understand how its unique scientific approach influences its valuation.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Lixte Biotechnology
Lixte Biotechnology, an oncology company developing a new class of drugs—phosphatase inhibitors—is extremely sensitive to scientific data. Its weekly stock price is a speculative reaction to the publication of preclinical and early clinical trial results that could confirm or refute the potential of its approach.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Lixte Biotechnology operates in the highly competitive oncology sector, where investor sentiment drives global trends. Any significant success or failure in the industry impacts everyone's risk appetite. The chart will show whether LIXT is following the general flow of biotech speculation or whether its unique scientific news is creating its own trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Lixte Biotechnology, as a biotech company, often ignores general market trends. Its fate depends not on GDP or inflation, but on the results of clinical trials. The chart below clearly demonstrates how LIXT shares can live their own life, separate from the broader market.
Market capitalization of the company, segment and market as a whole
LIXT - Market capitalization of the company Lixte Biotechnology
Lixte Biotechnology's chart is a bet on a new approach to cancer treatment. The company's market cap reflects investor hopes for its drugs, which are expected to make tumors more vulnerable to standard therapy. Its dynamics represent a highly speculative market assessment of the potential of this breakthrough, yet unproven, technology.
LIXT - Share of the company's market capitalization Lixte Biotechnology within the market segment - General oncology therapy
Lixte Biotechnology develops drugs that inhibit key enzymes involved in cancer development. Its market share in the oncology sector is based on the potential of its unique mechanism of action. The chart shows investor assessments of its ability to create effective combinations with existing chemotherapies.
Market capitalization of the market segment - General oncology therapy
Lixte Biotechnology develops drugs that make cancer cells more vulnerable to standard treatments. The chart below shows the market capitalization of the oncology sector. This represents a market where finding new combinations and approaches is key to defeating the disease.
Market capitalization of all companies included in a broad market index - GURU.Markets
Lixte Biotechnology is an oncology company developing drugs that make cancer cells more vulnerable to chemotherapy. Its market cap is a bet on this synergistic approach. The chart below shows the weightings of companies that are improving treatment effectiveness.
Book value capitalization of the company, segment and market as a whole
LIXT - Book value capitalization of the company Lixte Biotechnology
Lixte Biotechnology's book value is its intellectual capital. The company's foundation consists of patents for its lead drug candidate, LB-100, which is designed to enhance the efficacy of chemotherapy, and funds for its clinical development. The chart below shows how the company uses its resources to test its scientific hypothesis.
LIXT - Share of the company's book capitalization Lixte Biotechnology within the market segment - General oncology therapy
Lixte Biotechnology, an oncology company, is focused on R&D. Its laboratories are its main physical asset. The S_BCap_Seg graph shows its small share of physical infrastructure, which is typical for a biotech company in clinical development.
Market segment balance sheet capitalization - General oncology therapy
Lixte Biotechnology is a clinical-stage oncology company. Its future depends on the success of its scientific developments. A book value chart shows that its assets are almost entirely intangible, a classic scenario for a biotech startup investing all its resources in research.
Book value of all companies included in the broad market index - GURU.Markets
Lixte Biotechnology's balance sheet is the capital for a fundamentally new approach to cancer treatment. The company's assets include the rights to its phosphatase inhibitors and the financial resources for clinical trials. The chart shows the resources available to test the hypothesis that its drugs could make existing cancer treatments significantly more effective.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Lixte Biotechnology
Lixte Biotechnology develops drugs that make cancer cells more vulnerable to traditional therapies. The company's book value is small. Its market capitalization reflects its unique scientific approach and the hope that its drugs will significantly improve the effectiveness of existing cancer treatments.
Market to book capitalization ratio in a market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage oncology company. Its value is determined solely by the potential of its drug candidates. The chart shows how much its market valuation, based on hopes for a scientific breakthrough, exceeds its current tangible assets, which is typical for the biotech sector.
Market to book capitalization ratio for the market as a whole
Lixte Biotechnology develops drugs that make cancer cells more vulnerable to standard therapy. The company's value lies in its innovative approach and patents. The chart shows how its market valuation reflects hopes for a scientific breakthrough in oncology, creating a huge gap with its book value.
Debts of the company, segment and market as a whole
LIXT - Company debts Lixte Biotechnology
Lixte Biotechnology, a clinical-stage oncology company, uses debt financing to test its scientific hypotheses. This chart shows the company's funding for clinical trials of its drugs, which could improve the effectiveness of standard cancer treatments. This represents a high-risk investment in a potentially breakthrough technology.
Market segment debts - General oncology therapy
Lixte Biotechnology is a clinical-stage oncology company. Its financial model is typical for biotech: all resources are devoted to research and development, and funding comes from investors through share sales. This chart is an indicator of its financial health, showing how much time it has to conduct trials before needing a new round of funding.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Lixte Biotechnology
Lixte Biotechnology develops oncology drugs. This chart reflects the company's capital structure and its reliance on debt. Financing breakthrough but risky cancer research with debt is rare. This metric helps understand the company's financial strategy as it works to develop a new drug.
Market segment debt to market segment book capitalization - General oncology therapy
Lixte Biotechnology is a company developing new approaches to cancer treatment. This chart for the biotech sector shows how the industry as a whole attracts capital to fund lengthy and expensive research. It provides context for assessing the financial viability of a company that does not yet have commercial products.
Debt to book value of all companies in the market
Lixte Biotechnology is developing drugs that improve the effectiveness of chemotherapy in cancer treatment. The pharmaceutical industry requires enormous investment. The dynamics of the debt-to-book value ratio across the market demonstrate how easily companies like Lixte can raise funds for research. A rise in this ratio may indicate investor optimism in the sector.
P/E of the company, segment and market as a whole
P/E - Lixte Biotechnology
Lixte Biotechnology develops drugs that make cancer cells more vulnerable to traditional treatments, such as chemotherapy. This chart is an indicator of hope for improved cancer treatment effectiveness. Its value reflects investors' belief in the company's technology's potential to change treatment standards and create a multi-billion dollar market.
P/E of the market segment - General oncology therapy
Lixte Biotechnology, like other biotechs, is in a high-risk and high-expectation sector. This chart shows the average P/E ratio for this industry. Comparing the company's P/E to this ratio allows us to understand how highly the market values its unique approach to improving the effectiveness of chemotherapy compared to other oncology developments.
P/E of the market as a whole
Lixte Biotechnology develops drugs that make cancer cells more vulnerable to traditional treatments, such as chemotherapy. This is an innovative approach in oncology. This chart shows the overall sentiment in the biotech sector. It helps us understand whether Lixte's technology stands out from other oncology developments and how the market views its chances of success.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Lixte Biotechnology
Lixte Biotechnology is a company developing new cancer treatments that enhance the effectiveness of standard chemotherapy and radiation therapy. The graph reflects speculative revenue expectations, which depend entirely on the success of clinical trials and the company's ability to demonstrate that its approach can improve cancer treatment outcomes.
%20P%2FE%20Lixte%20Biotechnology&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Lixte-Biotechnology&v=1772513481026 "Chart of the company's future (projected) P/E Lixte Biotechnology")
Future (projected) P/E of the market segment - General oncology therapy
Lixte Biotechnology develops drugs that inhibit key enzymes involved in cancer cell division, aiming to enhance the effectiveness of standard chemotherapy and radiotherapy. This chart shows how its future revenue expectations compare to the oncology industry average, reflecting its belief in its scientific hypothesis.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772513481052 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Lixte Biotechnology is a clinical-stage company developing a new class of drugs that make cancer cells more vulnerable to traditional chemotherapy. Its valuation is a bet on a scientific breakthrough in oncology. It is not tied to general market expectations, but rather depends on research data.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513481087 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Lixte Biotechnology
Lixte Biotechnology is a clinical-stage company developing drugs that inhibit key enzymes involved in cancer development. Its financial statements currently reflect research and development expenses. This chart shows how the company is investing in the development of a new class of anticancer drugs targeting fundamental cancer mechanisms.
Profit of companies in the market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage company developing phosphatase inhibitors to improve the effectiveness of chemotherapy in cancer treatment. This chart reflects the overall profitability of the oncology sector. Lixte's contribution to current profit is negative due to research costs, but its technology has the potential to dramatically improve existing treatments and drive growth in the segment.
Overall market profit
Lixte Biotechnology is a clinical-stage company developing new cancer treatments. Its future is determined solely by scientific results and the potential of its drugs. Against the backdrop of general economic cycles, as reflected in this chart, Lixte is working to develop breakthrough technologies capable of changing approaches to oncology, regardless of market conditions.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Lixte Biotechnology
Lixte Biotechnology is a clinical-stage company developing drugs that enhance the effectiveness of standard cancer treatments. This chart reflects analysts' forecasts for future revenue, which will only become possible after successful clinical trials and approval. Its dynamics demonstrate the market's confidence in the company's innovative approach to oncology.
%20profit%20of%20the%20company%20Lixte%20Biotechnology&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Lixte-Biotechnology&v=1772513481260 "Graph of future (projected) profit of the company Lixte Biotechnology")
Future (predicted) profit of companies in the market segment - General oncology therapy
Lixte Biotechnology Holdings is focused on developing a new class of oncology drugs that improve the effectiveness of standard cancer treatments. This chart shows profitability forecasts for the oncology sector. It reflects expectations for innovative approaches to cancer treatment that could change the standard of care and commercial prospects.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772513481277 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
Lixte Biotechnology is developing new cancer treatments. Funding for such cutting-edge research is directly dependent on market sentiment. The total return forecast chart shows whether investors are willing to invest in long-term, risky biotech projects. Rising expectations open the door to capital, while falling expectations close it.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513481295 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Lixte Biotechnology
Lixte Biotechnology is a company developing cancer treatments. While in clinical trials, it does not yet generate sales revenue. Its P/S ratio will be a key indicator after commercialization, reflecting the market's assessment of the effectiveness of its innovative approach to oncology and the potential market size.
P/S market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage company developing a new class of drugs that enhance the effectiveness of chemotherapy and radiation therapy in cancer treatment. Their approach could enhance existing treatments. The chart demonstrates the market's confidence in their technology and its potential to generate revenue in the future oncology landscape.
P/S of the market as a whole
Lixte Biotechnology is a biotech company developing new drugs to treat cancer. The company has no revenue, and its valuation is entirely dependent on the success of clinical trials. This chart, showing how the market values real revenue, clearly demonstrates that Lixte is a venture bet on a scientific breakthrough in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Lixte Biotechnology
Lixte Biotechnology is developing a new class of drugs that make cancer cells more vulnerable to traditional treatments. This is a potentially revolutionary approach. This chart reflects investor expectations for future revenue, which could be enormous if the company's technology proves effective in improving the effectiveness of chemotherapy.
%20P%2FS%20Lixte%20Biotechnology&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Lixte-Biotechnology&v=1772513481445 "The graph of the company's future (projected) P/S Lixte Biotechnology")
Future (projected) P/S of the market segment - General oncology therapy
Lixte Biotechnology Holdings, Inc. is a pharmaceutical company developing novel phosphatase inhibitors to enhance the effectiveness of chemotherapy in cancer treatment. This chart shows how the market views the future potential of its unique approach to oncology. It compares it to other companies, reflecting the hopes that its technology will enhance existing treatments.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772513481463 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Lixte Biotechnology develops drugs that enhance the effectiveness of standard chemotherapy. It is an innovative approach to cancer treatment, aiming to improve existing methods. This chart illustrates overall revenue expectations, and Lixte demonstrates how scientific developments that can improve the effectiveness of medicine shape growth expectations.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513481484 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Lixte Biotechnology
Lixte Biotechnology is a clinical-stage biotechnology company focused on developing novel cancer treatments. Because the company is in the research and development phase, it does not yet have any approved drugs. Therefore, revenue is typically not included in this chart, and its operations are funded by private equity.
Sales of companies in the market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage company developing new cancer treatments. At this stage, its revenue, if any, may come from licensing agreements or grants. This graph allows investors to assess external financial support, which is critical to continuing expensive research.
Overall market sales
Lixte Biotechnology Holdings is a company developing new cancer treatments. Its operations are at the forefront of science, and its value is determined by the potential of its developments. This overall economic performance schedule is irrelevant to Lixte, for which successful clinical trials, not market cycles, are key events.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Lixte Biotechnology
Lixte Biotechnology is a clinical-stage company developing drugs that make cancer tumors more vulnerable to traditional treatments. Its revenue forecast is entirely dependent on the success of its research. This chart shows analysts' speculative estimates of its potential in the oncology field.
%20sales%20of%20the%20company%20Lixte%20Biotechnology&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Lixte-Biotechnology&v=1772513481675 "Schedule of future (projected) sales of the company Lixte Biotechnology")
Future (projected) sales of companies in the market segment - General oncology therapy
Lixte Biotechnology develops new classes of drugs to treat oncology diseases. This chart reflects projected revenues for the entire oncotherapy segment. It provides insight into overall investment sentiment and expected growth in the cancer drug market, which is critical context for a small biotech company like Lixte.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772513481726 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Lixte Biotechnology is a clinical-stage company developing new drugs for the treatment of cancer. Its value is determined by the potential of its scientific developments, not by current sales. This chart of overall market expectations reflects investor risk appetite, which is critical for funding long-term and capital-intensive projects in the biotech sector.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513481740 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Lixte Biotechnology
Lixte Biotechnology is a company developing new approaches to cancer treatment. This chart reflects the company's financial performance at the advanced preclinical and clinical research stages. It shows the company's investment in research, and its future ability to generate profits depends entirely on the success of its innovative drug candidates.
Market segment marginality - General oncology therapy
Lixte Biotechnology is a company developing new classes of anticancer drugs targeting key enzymes that regulate cell division. This chart shows the average profitability in the oncology therapeutics sector. It allows one to evaluate the potential cost-effectiveness of Lixte's developments compared to existing industry standards.
Market marginality as a whole
Lixte Biotechnology Holdings is focused on developing a new class of cancer treatments. Like many biotech companies, it operates in a high-risk, high-return environment. This average market return chart doesn't reflect the specifics of its business, which depends solely on scientific discoveries and clinical trial results.
Employees in the company, segment and market as a whole
Number of employees in the company Lixte Biotechnology
Lixte Biotechnology is a clinical-stage company developing phosphatase inhibitors for cancer treatment. Its extremely small team reflects a business model focused exclusively on R&D. This chart illustrates how a minimal team, yet with deep scientific expertise, can advance an innovative therapeutic platform.
Share of the company's employees Lixte Biotechnology within the market segment - General oncology therapy
Lixte Biotechnology Holdings is a clinical-stage company developing a new class of cancer treatments. This chart highlights its innovative focus. It reflects the percentage of oncologists and researchers working on phosphatase inhibitors—a new approach to improving the effectiveness of chemotherapy—that this driven company brings together under its wing.
Number of employees in the market segment - General oncology therapy
Lixte Biotechnology Holdings is developing a new class of anti-cancer drugs. This chart shows the workforce in the oncology therapeutics sector. The growing number of scientists and clinicians indicates a global increase in investment in the fight against cancer and the search for fundamentally new treatment approaches, creating a fertile environment for Lixte's breakthrough research.
Number of employees in the market as a whole
Lixte Biotechnology Holdings is focused on developing new cancer treatments. Investments in biotechnology stimulate job creation for scientists and researchers. This chart reflects overall employment, where cutting-edge companies like Lixte are laying the foundation for future medical and economic breakthroughs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Lixte Biotechnology (LIXT)
Lixte Biotechnology, an oncology company, is another example of a company whose value lies in its research. The high market capitalization per employee, illustrated by this chart, indicates that the market highly values their scientific platform and the potential of future cancer drugs developed by the Lixte team.
%20of%20the%20company%20Lixte%20Biotechnology%20(LIXT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Lixte-Biotechnology-LIXT&v=1772513481897 "Chart of market capitalization per employee (in thousands of dollars) of the company Lixte Biotechnology (LIXT)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage oncology company. Its value lies in its pipeline of potential drugs. Its market valuation per employee is essentially a bet investors are making on the company's future R&D success. Its outperformance from the sector average reflects the market's high appreciation for the uniqueness of its scientific approach.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772513481914 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Lixte Biotechnology is developing a new class of cancer treatments. In early-stage oncology, all the value is in the science. This chart illustrates investor expectations: a high valuation per employee reflects confidence in the company's scientific team's ability to demonstrate the effectiveness of its breakthrough approach.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513481925 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Lixte Biotechnology (LIXT)
Lixte Biotechnology is a clinical-stage company developing new cancer treatments (phosphatase inhibitors). It's a pure R&D business. This chart, in negative territory, shows the cost of maintaining an elite team of scientists and researchers who are burning through investors' capital in pursuit of breakthroughs in oncology.
%20Chart%20Lixte%20Biotechnology%20(LIXT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Lixte-Biotechnology-LIXT&v=1772513481930 "Company Profit Per Employee (in thousands of dollars) Chart Lixte Biotechnology (LIXT)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Lixte Biotechnology develops new cancer treatments targeting previously inaccessible targets. In the field of oncology, breakthrough ideas are especially valuable. This graph demonstrates how effectively a small research team can generate intellectual property with enormous commercial potential, a key indicator of the return on investment in biotechnology.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772513481946 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Lixte Biotechnology is a company developing new cancer treatments. In the oncology field, R&D requires significant investment. This chart shows the R&D investment per team member. Positive growth in the future will indicate successful commercialization of their phosphatase inhibitor platform and high returns on their scientific staff.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513481972 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Lixte Biotechnology (LIXT)
Lixte Biotechnology Holdings is an early-stage oncology company. This graph, showing zero revenue per employee, is typical for biotech. It reflects a period when all resources are focused on research and clinical trials. Commercial success in the future could lead to explosive growth in this metric.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Lixte-Biotechnology-LIXT&v=1772513481983 "Sales chart per company employee Lixte Biotechnology (LIXT)")
Sales per employee in the market segment - General oncology therapy
Lixte Biotechnology (LIXT) is a biopharmaceutical company developing protein phosphatase (PP2A) inhibitors for the treatment of oncology. This is a fundamental approach to cancer therapy. This chart shows the average revenue per employee in the pharmaceutical segment. For Lixte, which is in clinical trials, comparison to this benchmark highlights their focus on R&D rather than commercial productivity.
Sales per employee for the market as a whole
Lixte Biotechnology is a clinical-stage biotech company focused on oncology. Similar to other R&D companies (Akari, Enlivex), this metric is currently approaching zero. It reflects the burn rate of its research team. Its future growth depends entirely on the success of clinical trials and approval of its drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Lixte Biotechnology (LIXT)
Lixte Biotechnology is a clinical-stage company betting on its drug to improve the effectiveness of standard cancer chemotherapy. This is a high-risk development. This chart shows the number of investors who don't believe in this scientific hypothesis. The bears are betting that the trials will fail, and the company, without any revenue, will go bankrupt.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Lixte-Biotechnology-LIXT&v=1772513482017 "Short Shares Chart for the Company Lixte Biotechnology (LIXT)")
Shares shorted by market segment - General oncology therapy
Lixte Biotechnology is a clinical-stage biotech developing a new class of cancer drugs. This chart shows the overall pessimism across the oncology industry. The growing short positions across the sector represent a bet that most trials will fail, or that new drugs will not be profitable due to pricing pressure. For LIXT, this means investors are generally skeptical of its entire scientific pipeline.
Shares shorted by the overall market
Lixte Biotechnology is pursuing new approaches to cancer treatment, targeting phosphatase inhibitors. This is fundamental science that requires extensive research. This chart measures overall fear. When the market is fearful, it doesn't reward "scientific projects." Investors see LIXT as a cash-burning company and prefer to exit the stock, fearing share dilution or trial failure.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Lixte Biotechnology (LIXT)
Lixte Biotechnology (LIXT) is developing a new class of cancer treatments targeting the PP2A enzyme. This is fundamental research, and the stock is highly speculative. This oscillator measures the speed of price movements. It shows when short bursts of enthusiasm (above 70) are fading, or when a decline (below 30) attracts speculative buyers.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Lixte-Biotechnology-LIXT&v=1772513482043 "RSI 14 indicator chart for the company's stock Lixte Biotechnology (LIXT)")
RSI 14 Market Segment - General oncology therapy
Lixte Biotechnology (LIXT) is a biotech company developing drugs that make cancer cells more vulnerable to chemotherapy and radiation. This chart measures overall sentiment in the Oncology sector. It helps distinguish Lixte's successful trials from general overheating or overselling across the biotech sector.
RSI 14 for the overall market
Lixte (LIXT) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an opportunity to easily raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast LIXT (Lixte Biotechnology)
Lixte (LIXT) is a biopharmaceutical company developing inhibitors (LB-100), which are believed to make standard chemotherapy more effective in the fight against cancer. This chart shows the speculative average price target from analysts, which is almost entirely dependent on their belief in the success of clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-LIXT-Lixte-Biotechnology&v=1772513482083 "A chart showing analyst consensus forecasts for the expected stock price. LIXT (Lixte Biotechnology)")
The difference between the consensus estimate and the actual stock price LIXT (Lixte Biotechnology)
Lixte Biotechnology is a biotech company developing inhibitors (LB-100) that are expected to make chemotherapy more effective. This chart shows the difference between the market valuation and the consensus forecast. It indicates whether experts believe in this R&D strategy to "amplify" existing cancer treatments.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-LIXT-Lixte-Biotechnology&v=1772513482090 "A chart showing the difference between the consensus forecast and the actual stock price. LIXT (Lixte Biotechnology)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Lixte Biotechnology (LIXT) is an early-stage biotech developing phosphatase inhibitors, a new class of drugs that make cancer more susceptible to chemotherapy. This chart shows the overall expectations for the general oncology sector, reflecting experts' confidence in this innovative R&D approach.
Analysts' consensus forecast for the overall market share price
Lixte Biotechnology (LIXT) is an early-stage biopharmaceutical company focused on cancer treatment. They are developing drugs that aim to "turn off" tumor defenses. This is highly speculative science. This chart shows the overall risk appetite, reflecting the market's willingness to fund the earliest and most risky R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Lixte Biotechnology
Lixte Biotechnology is a clinical-stage biotech company focused on oncology. Their signature drug is phosphatase inhibitors (PP2A), a new class of drugs that they theorize could make existing chemotherapies (like Doxorubicin) significantly more effective. This chart is a pure indicator of their R&D, reflecting their progress in clinical trials and their combination strategy.
AKIMA Market Segment Index - General oncology therapy
Lixte Biotechnology (LIXT) is an oncology company developing phosphatase inhibitors (LB-100). Their approach is to make existing chemotherapy and radiotherapy more effective by preventing cancer cells from regenerating. The chart shows the segment average index, helping investors assess how this therapy-boosting strategy compares to the average.
The AKIM Index for the overall market
Lixte Biotechnology is developing protein phosphatase inhibitors (LB-100) to improve the effectiveness of cancer chemotherapy and immunotherapy. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this scientific concept compares to overall economic trends.
